Coronavirus: AIIMS Delhi to begin enrolling volunteers for Covaxin trials from Monday

Modesto Morganelli
Luglio 19, 2020

Amid the infections and recoveries, several countries such as India, Russia, US, UK are fast-tracking their processes to develop a vaccine for the virus.

Redkar Hospital, located in North Goa's Pernem taluka, is amongst the 12 facilities that are listed for human trials of Covaxin developed by Bharat Biotech International Limited.

Human trials for the university's vaccine began on July 13. The hospital has already got the approval from its ethics committee to commence the human trials and the hospital will enroll a total of 100 volunteers, according to the Indian Express.

The phase I and II clinical trials of the vaccine for SARS-CoV-2 by Bharat Biotech have been approved by the Indian drug regulator after pre-clinical studies demonstrated safety and immune response. "The data was submitted to the Drugs Controller General of India (DCGI) following which both these candidate vaccines got clearance to start the early phase of human trials", he had said.

Procurement Minister Anita Anand says Ottawa intends to stockpile enough vaccine supplies to be able to give at least two doses to every Canadian whenever a vaccine is available.

China has positioned itself to be a strong contender.

Trials have started at AIIMS, Patna and few other places. They were administered the vaccine twice within 28 days and the researchers saw development of anti-bodies in them.

ICMR has informed that institutions in India are developing the vaccine prototypes only after complying with every necessary rules and regulation stratified by worldwide customs since no compromises are being made in the attempt to ahead in the race for coronavirus vaccine.

Eight of the almost two dozen potential vaccines in various stages of human testing worldwide are from China, the most of any country.

Last week, Sheikh Abdullah bin Mohammed Al Hamed, chairman of the Department of Health Abu Dhabi, became the first volunteer to take part in the trial.

"We expect to have sufficient vaccine for the entire Australian population as part of the CSL agreement".

Volunteers have started receiving the first doses of the vaccine, officials said. We are going to select healthy participants with no comorbidities and without a history of COVID-19. It evaluated three doses that were given in a two-shot regimen.

Germany has reached the second stage of Covid-19 vaccine development while Australian companies are still on the first stage.

Altre relazioniGrafFiotech

Discuti questo articolo

Segui i nostri GIORNALE